Physician profile
John W Thomas
NPI 1811998594
$9,042.53
in general payments reported to CMS, 2019-2025
28 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,868 · 2020: $312 · 2021: $730 · 2022: $770 · 2023: $671 · 2024: $230 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,998.26 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $680.33 | 2019-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $301.19 | 2022-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $276.58 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $195.07 | 2023 | Syfovre |
| Abbvie INC. | $174.28 | 2022-2025 | Durysta, Ozurdex |
| Astellas Pharma US INC | $174.10 | 2023-2025 | Izervay |
| Alcon Vision LLC | $126.79 | 2022-2024 | Rocklatan, Simbrinza |
| Regeneron Healthcare Solutions, INC. | $125.19 | 2019-2023 | Eylea Hd |
| Amgen INC. | $124.02 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $122.28 | 2024-2025 | Vevye |
| Glaukos Corporation | $100.97 | 2021-2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $83.47 | 2019-2021 | |
| Oyster Point Pharma, INC. | $75.65 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $69.06 | 2022-2025 | Xiidra, Vyzulta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $67.41 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $62.86 | 2019-2021 | |
| Horizon Therapeutics Plc | $57.93 | 2021-2023 | Tepezza |
| Iridex Corporation | $39.76 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $33.42 | 2024-2025 | Humphrey Hfa, Forum |
| Springworks Therapeutics, INC. | $28.70 | 2025 | Gomekli |
| Glaxosmithkline, LLC. | $25.88 | 2025 | Blenrep |
| Eyepoint US, INC. | $24.42 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.23 | 2021 | |
| Ocular Therapeutix, INC. | $17.22 | 2019 | |
| Biotissue Holdings INC. | $16.97 | 2023 | |
| Rxsight INC | $11.71 | 2022 | |
| Alimera Sciences, INC. | $10.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.